市場調查報告書

薛格連氏症候群:市場分析/流行病學/市場預測(-2030年)

Sjogren's syndrome - Market Insights, Epidemiology, and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 955305
出版日期 內容資訊 英文 207 Pages
商品交期: 最快1-2個工作天內
價格
薛格連氏症候群:市場分析/流行病學/市場預測(-2030年) Sjogren's syndrome - Market Insights, Epidemiology, and Market Forecast - 2030
出版日期: 2020年08月01日內容資訊: 英文 207 Pages
簡介

2017年,七個主要國家的薛格連氏症候群(SS)病例數估計為3,179,223。

在此報告中,薛格連氏症候群的流行病,治療藥物,新興藥物,每種治療藥物的市場佔有率以及7個主要市場(美國,德國,西班牙,意大利,法國,英國,日本)的市場趨勢我們正在分析預測,未滿足的需求等。

目錄

第1章主要討論

第2章薛格連氏症候群(SS):市場概述

  • 2017年SS的市場佔有率(%)分佈
  • 2030年SS的市場佔有率(%)分佈

第3章組織

第4章執行摘要

第5章疾病概述:薛格連氏症候群

  • 簡介
  • 薛格連氏症候群的分類
  • 前兆和症狀
  • 病因
  • 發病機理
  • 薛格連氏症候群的生物標誌物
  • 薛格連氏症候群的診斷
    • 鑑別診斷

第6章流行病學和患者人群

  • 主要發現
  • 在7個主要市場中被診斷出患有薛格連氏症候群的患者總數
  • 薛格連氏症候群流行病學:按國家
  • 美國
    • 假設和依據
    • 美國現有Schegren綜合徵病例
    • 美國薛格連氏症候群病例:性別
    • 美國薛格連氏症候群病例:按類型
    • 美國薛格連氏症候群病例:按嚴重程度
  • 德國
  • 法國
  • 意大利
  • 西班牙
  • 英國
  • 日本

第7章當前治療方法

  • 美國針對薛格連氏症候群的治療指南
  • 循證臨床指南(美國,歐盟,日本)

第8章未滿足的需求

第9章非處方藥

  • Salagen:ADVANZ Pharma
    • 藥物說明
    • 監管里程碑
    • 安全性和有效性
    • 產品簡介
  • Evoxac:Daiichi Sankyo
    • 臨床發展

第10章新補救措施

  • 主要競爭對手:新療法
  • VAY736:Novartis/MorphoSys
    • 藥物說明
    • 其他發展活動
    • 臨床發展
    • 安全性和有效性
    • 產品簡介
  • RSLV-132:Resolve Therapeutics
  • Belimumab:GlaxoSmithKline
  • VIB4920:VIELABIO
  • RC18:RemeGen
  • Branebrutinib:Bristol Myers Squibb
  • LOU-064:Novartis
  • CFZ533:Novartis

第11章其他可能的補救方法

  • Lacripep:TearSolutions
    • 產品說明
    • 其他發展活動
    • 臨床發展
    • 產品簡介
  • Parsaclisib:Incyte Corporation
    • 藥物說明
  • Filgotinib, Lanraplenib, Tirabrutinib: Galapagos NV/Gilead Sciences
    • 其他發展活動

第12章薛格連氏症候群:7個主要市場的分析

  • 主要發現
  • 薛格連氏症候群市場規模(7個主要國家)

第13章每個國家/地區的市場前景

  • 美國市場規模
    • 薛格連氏症候群的總市場規模
    • 原發性薛格連氏症候群的市場規模:按治療藥物分
    • 繼發性薛格連氏症候群的市場規模:按治療藥物分

第14章:五個歐洲國家:市場前景

  • 德國
    • 薛格連氏症候群的總市場規模
    • 原發性薛格連氏症候群的市場規模:按治療藥物分
    • 繼發性薛格連氏症候群的市場規模:按治療藥物分
  • 法國
  • 意大利
  • 西班牙
  • 英國
  • 日本:市場前景

第15章市場增長因素

第16章市場壁壘

第17章SWOT分析

第18章案例研究

  • 罕見的薛格連氏症候群伴顱內出血
  • 病例報告:薛格連氏症候群和視神經脊髓炎譜系障礙
  • 巨噬細胞活化綜合徵,原發性薛格連氏症候群的罕見併發症:病例報告

第19章市場准入和醫療費用報銷

第20章KOL的觀點

第21章附錄

第22章報告調查方法

第23章:Delve Insight Services

第24章免責聲明

第25章:關於Delve Insight

目錄
Product Code: DIMI0339

DelveInsight's 'Sjogren's syndrome (SS) - Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the Sjogren's syndrome (SS), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Sjogren's syndrome (SS) market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted SS symptoms market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Sjogren's syndrome (SS) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Sjogren's syndrome (SS) Disease Understanding and Treatment Algorithm

Sjogren's syndrome (SS) Overview

Sjogren's syndrome (SS) is an autoimmune disorder caused by the lymphocytic infiltration of exocrine glands resulting in glandular dysfunction, preferentially of the salivary and lacrimal glands. It can be classified into two types, i.e., primary Sjogren's syndrome, and secondary Sjogren's syndrome. Primary Sjogren's syndrome (pSS) occurs in the absence of other autoimmune diseases and is characterized by keratoconjunctiva sicca (dry eyes) and xerostomia (dry mouth), collectively called the sicca syndrome. In contrast, secondary Sjogren's syndrome presents, along with other autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

Currently, the pathogenesis of the diseases is not fully understood and is currently thought to be the result of a combination of factors such as genetic defects, immune mechanisms, and virus infections. Increased activation of B cells followed by immune complex formation and autoantibody production, in particular, anti-Ro/SS-A and anti-La/SS-B are thought to play important roles.

Sicca symptoms are the hallmarks of the disease, which may also present with various organ manifestations. There is no single disease-specific diagnostic criterion for SS. The diagnosis of SS is a complex task that cannot be readily done. No sign, symptom, or test is unique to this syndrome. The diagnosis of SS is based on the combination of sicca symptoms and the presence of the autoimmune phenomena characterized by the activation of T and/or B cells. Also, for many years the diagnosis of SS lacked standardization

The diagnosis of SS is made based on medical history, physical examination, specific ocular, oral evaluation, blood tests, and salivary gland assessment (biopsy and ultrasound).

Sjogren's syndrome (SS) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Sjogren's syndrome (SS) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Sjogren's syndrome (SS) market report gives a thorough understanding of SS symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides SS symptoms of treatment algorithms and treatment guidelines for SS symptoms in the US, Europe, and Japan.

Sjogren's syndrome (SS) Epidemiology

The Sjogren's syndrome symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Sjogren's syndrome (SS) epidemiology segmented as the Diagnosed Prevalent Cases of Sjogren's syndrome, Gender-Specific Cases of Sjogren's syndrome, Type-Specific Cases of Sjogren's syndrome, Severity-Specific Cases of Sjogren's syndrome. The report includes the prevalent scenario of SS symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Sjogren's syndrome (SS) Epidemiology

The epidemiology segment also provides the Sjogren's syndrome (SS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total prevalent cases of Sjogren's syndrome (SS) in 7MM countries were estimated to be 3,179,223 cases in 2017.

Sjogren's syndrome (SS) Drug Chapters

The drug chapter segment of the Sjogren's syndrome (SS) report encloses the detailed analysis of SS marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Sjogren's syndrome (SS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

The therapeutic market size of Sjogren's syndrome is mainly accounted by symptomatic treatment including local therapies, systemic therapies, and immunosuppressants (Methotrexate (MTX), Cyclosporine A, Azathioprine, Leflunomide, and Mycophenolic acid). Moreover, Biological therapies such as Rituximab is in extensive use for the US market.

Products detail in the report…

Sjogren's syndrome (SS) Emerging Drugs

VAY736 (Ianalumab) (Novartis/MorphoSys)

It is a novel, intravenous, defucosylated, monoclonal antibody that targets the human B cell-activating factor (BAFF) of the TNF family. It is engineered to effectively eliminate B cells from circulation in vivo by antibody-dependent cellular cytotoxicity (ADCC). The ADCC activity of Ianalumab is greatly enhanced by the elimination of fucose residues from the carbohydrate moiety attached to the Fc part of the antibody. The molecule is being developed by the Novartis in partnership with MorphoSys as an antibody-based therapy. It is currently in Phase II clinical studies for the treatment of primary Sjogren's Syndrome.

Products detail in the report…

Sjogren's syndrome (SS) Market Outlook

The Sjogren's syndrome (SS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Sjogren's syndrome (SS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Sjogren's syndrome (SS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Sjogren's syndrome (SS) market in 7MM is expected to change in the study period 2017-2030.

The local therapies mainly include pilocarpine, cevimeline, topical fluoride, topical cyclosporine, autologous serum eye drops, and others. Systemic therapy mainly uses corticosteroids, hydroxychloroquine, and immunosuppressants. Methotrexate (MTX), Cyclosporine A, Azathioprine, Leflunomide, and Mycophenolic acid are also commonly used DMARDs. Biological therapy with Rituximab is in extensive use for the US market. Along with this, TNF- alpha inhibitors, BAFF, and others are in the development.

Key Findings

This section includes a glimpse of the Sjogren's syndrome (SS) market in 7MM. The market size of SS in the seven major markets was found to be USD 1,699.8 Million in 2017.

The United States Market Outlook

This section provides a total of Sjogren's syndrome (SS) market size and market size by therapies in the United States.

The United States accounts for the highest market size of SS in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Local therapy generally includes the treatment of sicca symptoms. For the treatment of dry eyes, tear substitution therapy consisting of high-viscosity eye drops and gels, in combination with oral mucolytic agents to dissolve mucus, is the mainstay treatment. Patients with Sjogren's syndrome associated severe or refractory keratoconjunctivitis sicca might require a short-term course of topical anti-inflammatory agents such as topical cyclosporine.

Drugs with a systemic effect, secretagogues, such as pilocarpine and cevimeline, are approved by the US FDA for the treatment of dry eyes and mouth in patients with Sjogren's syndrome. Both drugs are muscarinic receptor agonists and induce a transient increase in salivary and lacrimal gland outputs in patients with some residual functional glandular tissue. Common adverse effects of these drugs include sweating, flushing, and the urgent need for urination and gastrointestinal discomfort, which might limit their clinical application.

EU-5 Countries: Market Outlook

The total Sjogren's syndrome (SS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

The therapeutic effect of hydroxychloroquine is based on the inhibition of TLR signaling, which affects the innate immune response by reducing the production of proinflammatory cytokines, such as type I IFNs, and other serological parameters. It is used as maintenance therapy in SS, based on the reduction of symptoms and improved serological parameters in patients with SLE and rheumatoid arthritis.

Methothrexate (MTX) is used in the treatment of arthritis in Sjogren's syndrome patients. Moreover, the usefulness of other immunosuppressive agents (such as cyclosporine A, azathioprine, methotrexate, leflunomide, and mycophenolic acid) has been evaluated in a small cohort of patients with SS. However, all these have high rates of adverse events

Japan Market Outlook

The total of Sjogren's syndrome (SS) market size and market size by therapies in Japan are also mentioned.

Sjogren's syndrome (SS) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Sjogren's syndrome (SS) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Sjogren's syndrome (SS) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Sjogren's syndrome (SS) key players involved in developing targeted therapeutics.

Major players include Belimumab (GlaxoSmithKline), RSLV-132 (Resolve Therapeutics), VAY736 (Novartis/MorphoSys), CFZ533 (Novartis), LOU-064 (Novartis), RC18 (Remgen), VIB4920 (Viela Bio), Branebrutinib (Bristol Myers Squib), Lacripep (TearSolutions) and others.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Sjogren's syndrome (SS) emerging therapies.

Reimbursement Scenario in Sjogren's syndrome (SS)

For Sjogren's Syndrome, no remitting agent exists and the treatment includes symptom palliation, prevention of complications. The frequent occurrence of oral and ocular complications mandates a multidisciplinary approach. For rheumatologists, proper selection of patients for immunosuppressive therapy is quite a challenge to optimize care. Unfortunately, the paucity of well-designed, controlled studies in the Sjogren's Syndrome medical and dental literature frequently leaves the clinician with little guidance. Therefore, the approach to treating SS in the United States has differed widely among various institutions and providers.

Several studies have documented that quality of life (QOL) is diminished in primary Sjogren's Syndrome (PSS) and found overall end-organ damage, as well as functional disability, comparable with lupus. Various studies found that the substantial use of healthcare services, with a mean annual total direct cost per Sjogren's patient, ranging between £2200 in the UK and USD 20, 000 in the USA.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Sjogren's syndrome (SS) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Sjogren's syndrome (SS) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive & Market Intelligence analysis of the Sjogren's syndrome (SS) Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Sjogren's syndrome (SS), explaining its causes, signs and symptoms, pathophysiology and currently available therapies
  • Comprehensive insight has been provided into the Sjogren's syndrome (SS) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Sjogren's syndrome (SS) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Sjogren's syndrome (SS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Sjogren's syndrome (SS) market

Report Highlights:

  • In the coming years, Sjogren's syndrome (SS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Sjogren's syndrome (SS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for SS. Launch of emerging therapies will significantly impact the Sjogren's syndrome (SS) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for SS.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Sjogren's syndrome (SS) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Sjogren's syndrome (SS) Pipeline Analysis
  • Sjogren's syndrome (SS) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Sjogren's syndrome (SS) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Sjogren's syndrome (SS) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Sjogren's syndrome (SS) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What were the Sjogren's syndrome (SS) Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Sjogren's syndrome (SS) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings of the market across 7MM and which country will have the largest Sjogren's syndrome (SS) market Size during the forecast period (2017-2030)?
  • At what CAGR, the Sjogren's syndrome (SS) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Sjogren's syndrome (SS) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Sjogren's syndrome (SS) market growth till 2030 and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of the Sjogren's syndrome (SS)?
  • What is the historical Sjogren's syndrome (SS) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What would be the forecasted patient pool of Sjogren's syndrome (SS) in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Sjogren's syndrome (SS)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Sjogren's syndrome (SS) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Sjogren's syndrome (SS)?
  • What are the current treatment guidelines for the treatment of Sjogren's syndrome (SS) in the USA, Europe, and Japan?
  • What are the Sjogren's syndrome (SS) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Sjogren's syndrome (SS)?
  • How many therapies are developed by each company for the treatment of Sjogren's syndrome (SS)?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Sjogren's syndrome (SS)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sjogren's syndrome (SS) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Sjogren's syndrome (SS) and their status?
  • What are the key designations that have been granted for the emerging therapies for Sjogren's syndrome (SS)?
  • What are the global historical and forecasted market of Sjogren's syndrome (SS)?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Sjogren's syndrome (SS) market
  • To understand the future market competition in the Sjogren's syndrome (SS) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Sjogren's syndrome (SS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Sjogren's syndrome (SS) market
  • To understand the future market competition in the Sjogren's syndrome (SS) market

Table of Contents

1. Key Insights

2. Sjogren's Syndrome (SS): Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of SS in 2017
  • 2.2. Market Share (%) Distribution of SS in 2030

3. Organizations

4. Executive summary

5. Disease Overview: Sjogren's syndrome

  • 5.1. Introduction
  • 5.2. Classification of Sjogren's Syndrome
  • 5.3. Signs and Symptoms
  • 5.4. Etiology
  • 5.5. Pathogenesis
  • 5.6. Biomarkers in Sjogren's Syndrome
  • 5.7. Diagnosis of Sjogren's Syndrome
    • 5.7.1. Differential Diagnosis

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. 7MM Total Diagnosed Prevalent Patient Population of Sjogren's Syndrome
  • 6.3. Country Wise-Epidemiology of Sjogren's syndrome
  • 6.4. United States
    • 6.4.1. Assumptions and Rationale
    • 6.4.2. Diagnosed Prevalent Cases of Sjogren's syndrome in the United States
    • 6.4.3. Gender-Specific Cases of Sjogren's syndrome in the US
    • 6.4.4. Type-Specific Cases of Sjogren's syndrome in the US
    • 6.4.5. Severity-Specific Cases of Sjogren's syndrome in the US
  • 6.5. Germany
    • 6.5.1. Assumptions and Rationale
    • 6.5.2. Diagnosed Prevalent Cases of Sjogren's syndrome in Germany
    • 6.5.3. Gender-Specific Cases of Sjogren's syndrome in Germany
    • 6.5.4. Type-Specific Cases of Sjogren's syndrome in Germany
    • 6.5.5. Severity-Specific Cases of Sjogren's syndrome in Germany
  • 6.6. France
    • 6.6.1. Assumptions and Rationale
    • 6.6.2. Diagnosed Prevalent Cases of Sjogren's syndrome in France
    • 6.6.3. Gender-Specific Cases of Sjogren's syndrome in France
    • 6.6.4. Type-Specific Cases of Sjogren's syndrome in France
    • 6.6.5. Severity-Specific Cases of Sjogren's syndrome in France
  • 6.7. Italy
    • 6.7.1. Assumptions and Rationale
    • 6.7.2. Diagnosed Prevalent Cases of Sjogren's syndrome in Italy
    • 6.7.3. Gender-Specific Cases of Sjogren's syndrome in Italy
    • 6.7.4. Type-Specific Cases of Sjogren's syndrome in Italy
    • 6.7.5. Severity-Specific Cases of Sjogren's syndrome in Italy
  • 6.8. Spain
    • 6.8.1. Assumptions and Rationale
    • 6.8.2. Diagnosed Prevalent Cases of Sjogren's syndrome in Spain
    • 6.8.3. Gender-Specific Cases of Sjogren's syndrome in Spain
    • 6.8.4. Type-Specific Cases of Sjogren's syndrome in Spain
    • 6.8.5. Severity-Specific Cases of Sjogren's syndrome in Spain
  • 6.9. United Kingdom
    • 6.9.1. Assumptions and Rationale
    • 6.9.2. Diagnosed Prevalent Cases of Sjogren's syndrome in the United Kingdom
    • 6.9.3. Gender-Specific Cases of Sjogren's syndrome in the United Kingdom
    • 6.9.4. Type-Specific Cases of Sjogren's syndrome in the UK
    • 6.9.5. Severity-Specific Cases of Sjogren's syndrome in the United Kingdom
  • 6.10. Japan
    • 6.10.1. Assumptions and Rationale
    • 6.10.2. Diagnosed Prevalent Cases of Sjogren's syndrome in Japan
    • 6.10.3. Gender-Specific Cases of Sjogren's syndrome in Japan
    • 6.10.4. Type-Specific Cases of Sjogren's syndrome in Japan
    • 6.10.5. Severity-Specific Cases of Sjogren's syndrome in Japan

7. Current Treatment Practices

  • 7.1. United States Treatment Guidelines for Sjogren's Disease
  • 7.2. Evidence-based medicine clinical practice guidelines (US, EU, JP)

8. Unmet Needs

9. Marketed Drugs

  • 9.1. Salagen: ADVANZ Pharma
    • 9.1.1. Drug Description
    • 9.1.2. Regulatory Milestones
    • 9.1.3. Safety and Efficacy
    • 9.1.4. Product Profile
  • 9.2. Evoxac: Daiichi Sankyo
    • 9.2.1. Drug Description
    • 9.2.2. Regulatory Milestones
    • 9.2.3. Clinical Development
    • 9.2.4. Safety and Efficacy
    • 9.2.5. Product Profile

10. Emerging Therapies

  • 10.1. Key cross competition- Emerging Therapies
  • 10.2. VAY736: Novartis/MorphoSys
    • 10.2.1. Drug Description
    • 10.2.2. Other Developmental Activities
    • 10.2.3. Clinical Development
    • 10.2.4. Safety and Efficacy
    • 10.2.5. Product Profile
  • 10.3. RSLV-132: Resolve Therapeutics
    • 10.3.1. Drug Description
    • 10.3.2. Other Developmental Activities
    • 10.3.3. Clinical Development
    • 10.3.4. Safety and Efficacy
    • 10.3.5. Product Profile
  • 10.4. Belimumab: GlaxoSmithKline
    • 10.4.1. Drug Description
    • 10.4.2. Other Developmental Activities
    • 10.4.3. Clinical Development
    • 10.4.4. Safety and Efficacy
    • 10.4.5. Product Profile
  • 10.5. VIB4920: VIELABIO
    • 10.5.1. Drug Description
    • 10.5.2. Other Developmental Activities
    • 10.5.3. Clinical Development
    • 10.5.4. Product Profile
  • 10.6. RC18: RemeGen
    • 10.6.1. Drug Description
    • 10.6.2. Clinical Development
    • 10.6.3. Product Profile
  • 10.7. Branebrutinib: Bristol Myers Squibb
    • 10.7.1. Drug Description
    • 10.7.2. Clinical Development
    • 10.7.3. Safety and Efficacy
    • 10.7.4. Product Profile
  • 10.8. LOU-064: Novartis
    • 10.8.1. Drug Description
    • 10.8.2. Clinical Development
    • 10.8.3. Safety and Efficacy
    • 10.8.4. Product Profile
  • 10.9. CFZ533: Novartis
    • 10.9.1. Drug Description
    • 10.9.2. Clinical Development
    • 10.9.3. Safety and Efficacy
    • 10.9.4. Product Profile

11. Other Potential therapies

  • 11.1. Lacripep: TearSolutions
    • 11.1.1. Product Description
    • 11.1.2. Other Development Activities
    • 11.1.3. Clinical Development
    • 11.1.4. Product Profile
  • 11.2. Parsaclisib: Incyte Corporation
    • 11.2.1. Drug Description
    • 11.2.2. Other Development Activities
    • 11.2.3. Clinical Development
    • 11.2.4. Product Profile
  • 11.3. Filgotinib, Lanraplenib, Tirabrutinib: Galapagos NV /Gilead Sciences
    • 11.3.1. Drug Description
    • 11.3.2. Other Developmental Activities
    • 11.3.3. Clinical Development
    • 11.3.4. Product Profile

12. Sjogren's Syndrome: 7 Major Market Analysis

  • 12.1. Key Findings
  • 12.2. Market Size of Sjogren's Syndrome in 7MM

13. Market Outlook by Country

  • 13.1. United States Market Size
    • 13.1.1. Total Market Size of Sjogren's syndrome
    • 13.1.2. Market Size of Primary Sjogren's syndrome by Therapies
    • 13.1.3. Market Size of Secondary Sjogren's syndrome by Therapies

14. EU-5 Countries: Market Outlook

  • 14.1. Germany
    • 14.1.1. Total Market Size of Sjogren's syndrome
    • 14.1.2. Market Size of Primary Sjogren's syndrome by Therapies
    • 14.1.3. Market Size of Secondary Sjogren's syndrome by Therapies
  • 14.2. France
    • 14.2.1. Total Market Size of Sjogren's syndrome
    • 14.2.2. Market Size of Primary Sjogren's syndrome by Therapies
    • 14.2.3. Market Size of Secondary Sjogren's syndrome by Therapies
  • 14.3. Italy
    • 14.3.1. Total Market Size of Sjogren's syndrome
    • 14.3.2. Market Size of Primary Sjogren's syndrome by Therapies
    • 14.3.3. Market Size of Secondary Sjogren's syndrome by Therapies
  • 14.4. Spain
    • 14.4.1. Total Market Size of Sjogren's syndrome
    • 14.4.2. Market Size of Primary Sjogren's syndrome by Therapies
    • 14.4.3. Market Size of Secondary Sjogren's syndrome by Therapies
  • 14.5. United Kingdom
    • 14.5.1. Total Market Size of Sjogren's syndrome
    • 14.5.2. Market Size of Primary Sjogren's syndrome by Therapies
    • 14.5.3. Market Size of Secondary Sjogren's syndrome by Therapies
  • 14.6. Japan: Market Outlook
    • 14.6.1. Total Market Size of Sjogren's syndrome
    • 14.6.2. Market Size of Primary Sjogren's syndrome by Therapies
    • 14.6.3. Market Size of Secondary Sjogren's syndrome by Therapies

15. Market Drivers

16. Market Barriers

17. SWOT Analysis

18. Case studies

  • 18.1. A rare case of Sjogren's Syndrome associated with Intracranial Hemorrhage
  • 18.2. Case Report: Sjogren's Syndrome plus Neuromyelitis Optica Spectrum Disorder
  • 18.3. Macrphage activation syndrome, a rare complication of primary Sjogren's syndrome: a case report

19. Market Access and Reimbursement

20. KOL Views

21. Appendix

22. Report Methodology

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

List of Tables

  • Table 1: American-European Consensus Group Criteria- Revised international classification criteria for Sjogren's syndrome
  • Table 2: Revised rules for classification - American-European Consensus Group Criteria
  • Table 3: ACR/EULAR criteria
  • Table 4: Selected Non-HLA genes implicated in SS
  • Table 5: Biomarkers in Primary Sjogren's syndrome
  • Table 6: Diagnostic tests to evaluate sicca symptoms in patients with Sjogren's Syndrome
  • Table 7: Evaluation of Dry Eye
  • Table 8: Comparison of the Revised AECG Classification criteria and the ACR Classification criteria for Sjogren's syndrome
  • Table 9: Diagnosed Prevalent Patient Population of Sjogren's syndrome in 7MM (2017-2030)
  • Table 10: Diagnosed Prevalent Cases of Sjogren's syndrome in the US (2017-2030)
  • Table 11: Gender-specific cases of Sjogren's syndrome in the US (2017-2030)
  • Table 12: Type-specific Cases of Sjogren's syndrome in the US (2017-2030)
  • Table 13: Severity specific Cases of Sjogren's syndrome in the United States (2017-2030)
  • Table 14: Diagnosed Prevalent Cases of Sjogren's syndrome in Germany (2017-2030)
  • Table 15: Gender-specific cases of Sjogren's syndrome in Germany (2017-2030)
  • Table 16: Type-specific Cases of Sjogren's syndrome in Germany (2017-2030)
  • Table 17: Severity specific Cases of Sjogren's syndrome in Germany (2017-2030)
  • Table 18: Diagnosed Prevalent Cases of Sjogren's syndrome in France (2017-2030)
  • Table 19: Gender-specific cases of Sjogren's syndrome in France (2017-2030)
  • Table 20: Type-specific Cases of Sjogren's syndrome in France (2017-2030)
  • Table 21: Severity specific Cases of Sjogren's syndrome in France (2017-2030)
  • Table 22: Diagnosed Prevalent Cases of Sjogren's syndrome in Italy (2017-2030)
  • Table 23: Gender-specific cases of Sjogren's syndrome in Italy (2017-2030)
  • Table 24: Type-specific Cases of Sjogren's syndrome in Italy (2017-2030)
  • Table 25: Severity specific Cases of Sjogren's syndrome in Italy (2017-2030)
  • Table 26: Diagnosed Prevalent Cases of Sjogren's syndrome in Spain (2017-2030)
  • Table 27: Gender-specific cases of Sjogren's syndrome in Spain (2017-2030)
  • Table 28: Type-specific Cases of Sjogren's syndrome in Spain (2017-2030)
  • Table 29: Severity specific Cases of Sjogren's syndrome in Spain (2017-2030)
  • Table 30: Diagnosed Prevalent Cases of Sjogren's syndrome in the UK (2017-2030)
  • Table 31: Gender-specific cases of Sjogren's syndrome in the UK (2017-2030)
  • Table 32: Type-specific Cases of Sjogren's syndrome in the UK (2017-2030)
  • Table 33: Severity specific Cases of Sjogren's syndrome in the UK (2017-2030)
  • Table 34: Diagnosed Prevalent Cases of Sjogren's syndrome in Japan (2017-2030)
  • Table 35: Gender-specific cases of Sjogren's syndrome in Japan (2017-2030)
  • Table 36: Type-specific Cases of Sjogren's syndrome in Japan (2017-2030)
  • Table 37: Severity specific Cases of Sjogren's syndrome in Japan (2017-2030)
  • Table 38: Oral management guidelines for caries prophylaxis
  • Table 39: Guidelines for DMARDS use for musculoskeletal pain in SS
  • Table 40: Guidelines for the treatment of fatigue in Sjogren's disease
  • Table 41: Guidelines for the use of biological medications in Sjogren's disease
  • Table 42: Currently available evidence-based medicine clinical practice guidelines on diagnosis and management of SS
  • Table 43: Evoxac, Clinical Trial Description, 2018
  • Table 44: Key Cross Competition, 2020
  • Table 45: Other Potential Therapies, 2020
  • Table 46: VAY736, Clinical Trial Description, 2020
  • Table 47: RSLV-132, Clinical Trial Description, 2020
  • Table 48: Belimumab, Clinical Trial Description, 2020
  • Table 49: VIB4920, Clinical Trial Description, 2020
  • Table 50: RC18, Clinical Trial Description, 2020
  • Table 51: Branebrutinib, Clinical Trial Description, 2020
  • Table 52: LOU-064, Clinical Trial Description, 2020
  • Table 53: CFZ533, Clinical Trial Description, 2020
  • Table 54: Lacripep, Clinical Trial Description, 2020
  • Table 55: Parsaclisib, Clinical Trial Description, 2020
  • Table 56: Filgotinib, Clinical Trial Description, 2020
  • Table 57: 7 Major Market Size of Sjogren's syndrome in USD Million (2017-2030)
  • Table 58: United States Market Size of Sjogren's syndrome in USD Million (2017-2030)
  • Table 59: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Table 60: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Table 61: Germany Market Size of Sjogren's syndrome in USD Million (2017-2030)
  • Table 62: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Table 63: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Table 64: France Market Size of Sjogren's syndrome in USD Million (2017-2030)
  • Table 65: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Table 66: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Table 67: Italy Market Size of Sjogren's syndrome in USD Million (2017-2030)
  • Table 68: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Table 69: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Table 70: Spain Market Size of Sjogren's syndrome in USD Million (2017-2030)
  • Table 71: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Table 72: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Table 73: UK Market Size of Sjogren's syndrome in USD Million (2017-2030)
  • Table 74: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Table 75: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Table 76: Japan Market Size of Sjogren's syndrome in USD Million (2017-2030)
  • Table 77: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Table 78: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2030)

List of Figures

  • Figure 1: Clinical spectrum Sjogren's syndrome
  • Figure 2: The Pathogenesis of autoimmune epitelitis as a potential explanation for Sjogren's Syndrome
  • Figure 3: Interplay of immune and non-immune factors in the pathophysiology of Sjogren's Syndrome
  • Figure 4: Diagnosed Prevalent Patient Population of Sjogren's syndrome in 7MM (2017-2030)
  • Figure 5: Diagnosed Prevalent Cases of Sjogren's syndrome in the United States (2017-2030)
  • Figure 6: Gender-specific Diagnosed Prevalent Cases of Sjogren's syndrome in the US (2017-2030)
  • Figure 7: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in the US (2017-2030)
  • Figure 8: Severity-specific Cases of Sjogren's syndrome in the US (2017-2030)
  • Figure 9: Diagnosed Prevalent Cases of Sjogren's syndrome in Germany (2017-2030)
  • Figure 10: Gender-specific of Sjogren's syndrome in Germany (2017-2030)
  • Figure 11: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in Germany (2017-2030)
  • Figure 12: Severity specific Cases of Sjogren's syndrome in Germany (2017-2030)
  • Figure 13: Diagnosed Prevalent Cases of Sjogren's syndrome in France (2017-2030)
  • Figure 14: Gender-specific Cases of Sjogren's syndrome in France (2017-2030)
  • Figure 15: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in France (2017-2030)
  • Figure 16: Severity specific Cases of Sjogren's syndrome in France (2017-2030)
  • Figure 17: Diagnosed Prevalent Cases of Sjogren's syndrome in Italy (2017-2030)
  • Figure 18: Gender-specific Cases of Sjogren's syndrome in Italy (2017-2030)
  • Figure 19: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in Italy (2017-2030)
  • Figure 20: Severity specific Cases of Sjogren's syndrome in Italy (2017-2030)
  • Figure 21: Diagnosed Prevalent Cases of Sjogren's syndrome in Spain (2017-2030)
  • Figure 22: Gender-specific Cases of Sjogren's syndrome in Spain (2017-2030)
  • Figure 23: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in Spain (2017-2030)
  • Figure 24: Severity specific Cases of Sjogren's syndrome in Spain (2017-2030)
  • Figure 25: Diagnosed Prevalent Cases of Sjogren's syndrome in the United Kingdom (2017-2030)
  • Figure 26: Gender-specific Cases of Sjogren's syndrome in the United Kingdom (2017-2030)
  • Figure 27: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in the UK (2017-2030)
  • Figure 28: Severity specific Cases of Sjogren's syndrome in the UK (2017-2030)
  • Figure 29: Diagnosed Prevalent Cases of Sjogren's syndrome in Japan (2017-2030)
  • Figure 30: Gender-specific Cases of Sjogren's syndrome in Japan (2017-2030)
  • Figure 31: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in Japan (2017-2030)
  • Figure 32: Severity -specific Cases of Sjogren's syndrome in Japan (2017-2030)
  • Figure 33: Unmet Needs of Sjogren's syndrome
  • Figure 34: 7 Major Market Size of Sjogren's syndrome in USD Million (2017-2030)
  • Figure 35: Market Size of Sjogren's syndrome in the United States, USD Millions (2017-2030)
  • Figure 36: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Figure 37: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Figure 38: Market Size of Sjogren's syndrome in Germany, USD Millions (2017-2030)
  • Figure 39: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Figure 40: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Figure 41: Market Size of Sjogren's syndrome in France, USD Millions (2017-2030)
  • Figure 42: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Figure 43: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Figure 44: Market Size of Sjogren's syndrome in Italy, USD Millions (2017-2030)
  • Figure 45: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Figure 46: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Figure 47: Market Size of Sjogren's syndrome in Spain, USD Millions (2017-2030)
  • Figure 48: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Figure 49: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Figure 50: Market Size of Sjogren's syndrome in the UK, USD Millions (2017-2030)
  • Figure 51: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Figure 52: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Figure 53: Market Size of Sjogren's syndrome in Japan, USD Millions (2017-2030)
  • Figure 54: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Figure 55: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2030)
  • Figure 56: Market Drivers
  • Figure 57:Market Barriers